Acacia Pharma Group plc, the latest UK biotech to have failed to make the grade as a commercial entity, is being snapped up by Eagle Pharmaceuticals, Inc. of the US for just €94.7m, despite having two approved hospital products drugs in a market potentially worth over $3bn.
Eagle Lands On COVID-Hit Acacia
Acquires UK Company For Under €95m
Acacia launched two hospital drugs – Barhemsys and Byfavo – in the US during COVID but failed to overcome the physical access limitations caused by the pandemic. Eagle of the US thinks it can tap into a potentially lucrative market and is buying the beleaguered biotech.
